- Home
- AXIL vs EQ Comparison
AXIL vs EQ Comparison
Compare AXIL & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXIL
- EQ
- Stock Information
- Founded
- AXIL 2015
- EQ 2017
- Country
- AXIL United States
- EQ United States
- Employees
- AXIL N/A
- EQ N/A
- Industry
- AXIL Package Goods/Cosmetics
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- AXIL Consumer Discretionary
- EQ Health Care
- Exchange
- AXIL Nasdaq
- EQ Nasdaq
- Market Cap
- AXIL 25.6M
- EQ 24.8M
- IPO Year
- AXIL N/A
- EQ 2018
- Fundamental
- Price
- AXIL $4.09
- EQ $0.71
- Analyst Decision
- AXIL
- EQ Buy
- Analyst Count
- AXIL 0
- EQ 2
- Target Price
- AXIL N/A
- EQ $5.00
- AVG Volume (30 Days)
- AXIL 5.2K
- EQ 288.2K
- Earning Date
- AXIL 01-09-2025
- EQ 11-13-2024
- Dividend Yield
- AXIL N/A
- EQ N/A
- EPS Growth
- AXIL 144.51
- EQ N/A
- EPS
- AXIL 0.24
- EQ N/A
- Revenue
- AXIL $27,243,542.00
- EQ $45,914,000.00
- Revenue This Year
- AXIL N/A
- EQ N/A
- Revenue Next Year
- AXIL N/A
- EQ N/A
- P/E Ratio
- AXIL $17.22
- EQ N/A
- Revenue Growth
- AXIL 7.30
- EQ 7.70
- 52 Week Low
- AXIL $3.54
- EQ $0.48
- 52 Week High
- AXIL $14.00
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- AXIL 49.55
- EQ 40.31
- Support Level
- AXIL $3.54
- EQ $0.68
- Resistance Level
- AXIL $4.00
- EQ $0.77
- Average True Range (ATR)
- AXIL 0.30
- EQ 0.07
- MACD
- AXIL -0.01
- EQ -0.01
- Stochastic Oscillator
- AXIL 53.16
- EQ 22.17
About AXIL AXIL Brands Inc. Common Stock
AXIL Brands Inc is a company which is is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, under the AXIL brand. AXIL delivers top hearing enhancement, protection, & audio devices. From ultra comfortable fitting processes, to stereo quality sound performance, to reliable & durable engineering.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.